


WHAT IS CLAIMED IS:

1. A compound of formula I:



FORMULA I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof, wherein,

- 10 R^1 represents C₆-10 aryl, C₅-10 heteroaryl or C₅-10 heterocyclic, said aryl, heteroaryl and heterocyclyl optionally substituted with 1 to 3 groups of R^a

- R^a represents C₁-6 alkyl, halogen, OH, aryl(C₁-6)alkyl, (C₁-6)alkoxy, (C₁-6)alkoxy(C₁-6)alkyl, halo(C₁-6)alkyl, nitro, amino, mono- or di-N-(C₁-6)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁-6)alkylcarbamoyl, (C₁-6)alkoxycarbonyl, aryloxy, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁-6)alkylthio, (C₁-6)alkylsulphonyl, (C₁-6)alkylsulphonyl, heterocyclyl, heterocyclyl(C₁-6)alkyl; and

- 20 R represents C₁-8 alkyl, C₃-10 cycloalkyl, C₃-10 heterocycloalkyl, C₅-10 heteroaryl, or C₅-11 heterocyclyl, said heteroaryl and heterocyclyl optionally substituted with 1 to 3 groups of R^a and said alkyl, optionally substituted with 1-3 groups selected from the group consisting of aryl, heterocyclyl, (C₁-6)alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino, ((2-amino)prop-2-yl)carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl, (C₂-6)alkenylthio, (C₂-6)alkynylthio, amino, mono- or di-(C₁-6)alkylamino, arylthio, heterocyclylthio, (C₁-6)alkoxy, aryl(C₁-6)alkoxy, aryl(C₁-6)alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen.


- 30 2. A compound according to claim 1 wherein R is a heterocycloalkyl and all other variables are as originally described.

3. A compound according to claim 1 wherein R is a heteroaryl and all other variables are as originally described.

4. A compound according to claim 1 wherein R¹ is a phenyl group optionally substituted with 1-3 groups of R^a and R is a heterocycloalkyl, or heteroaryl group.



















5. A compound according to claim 1 wherein R¹ is a phenyl group substituted with 1 to 3 groups of methoxy, halogen, methyl, ethyl, propyl, butyl, naphthyl, 5-(2-pyridyl)thiophen-2-yl or a mixture thereof, and R a heterocycloalkyl or heteroaryl.





















6. A compound according to claim 1 which is selected from the group consisting of:
 15 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 20 acetamide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-
 cyclopropylbutyramide; and from tables 1 and 2 below













































25























Example #	R1	R2
3		





















4		
5		
6		
7		
8		
9		
10		
11		
12		





















13		
14		
15		
16		
17		
18		
19		
20		
21		
22		





















23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		























34		
35		
36		
37		
38		
39		
40		
41		
42		
43		



















44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		





















55		
56		
57		
58		
59		
60		
61		
62		
63		
64		

























65		
66		
67		
68		
69		
70		
71		
72		
73		
74		

























75		
76		
77		
78		
79		
80		
81		
82		
83		
84		

85		
86		
87		
88		
89		
90		
91		
92		
93		
94		
95		

96		
97		
98		
99		
100		
101		
102		
103		
104		

105		
106		
107		
108		
109		
110		
111		
112		
113		
114		

115		
116		
117		
118		
119		
120		
121		
122		
123		
124		
125		
126		

127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		
138		






















139		
140		
141		
142		
143		
144		

Table 2



Example #	R1	R2
146		Me
147		Me

148		Me
149		H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, enantiomers, diastereomers or in vivo hydrolysable esters or mixtures thereof.


7. A compound according to claim 6 which is selected from the group consisting of:
- 5 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide;
- 10 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-
 cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers,
 diastereomers or in vivo hydrolysable esters or mixtures thereof.

15

8. A compound according to claim 7 which is:
- N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide; or
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide; or pharmaceutically acceptable salts, enantiomers, diastereomers or in vivo
 20 hydrolysable esters or mixtures thereof.

9. A composition according to claim 1, comprising a compound of formula I and a pharmaceutically acceptable carrier.

10. A method of inhibiting the activity of lethal factor (LF) released from bacteria in a mammal comprising administration to a patient in need thereof a therapeutically effective amount of a compound of structural formula I



FORMULA I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof, wherein,

R¹ represents C₆₋₁₀ aryl, C₅₋₁₀ heteroaryl or C₅₋₁₀ heterocyclic, said aryl, heteroaryl and heterocyclyl optionally substituted with 1 to 3 groups of R^a


R^a represents C₁₋₆ alkyl, halogen, OH, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, nitro, amino, mono- or di-N-(C₁₋₆)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxy carbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl, heterocyclyl(C₁₋₆)alkyl; and

R represents C₁₋₈ alkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₅₋₁₀ heteroaryl, or C₅₋₁₁ heterocyclyl, said heteroaryl and heterocyclyl optionally substituted with 1 to 3 groups of R^a and said alkyl, optionally substituted with 1-3 groups selected from the group consisting of aryl, heterocyclyl, (C₁₋₆)alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino, ((2-amino)prop-2-yl)carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl, (C₂₋₆)alkenylthio, (C₂₋₆)alkynylthio, amino, mono- or di-(C₁₋₆)alkylamino, arylthio, heterocyclylthio, (C₁₋₆)alkoxy, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen.

11. A method according to claim 11 wherein the compound is selected from the group consisting of:





















- N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide;
 5. N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-
 cyclopropylbutyramide; and from tables 1 and 2 below





















Table1











































10























Example #	R1	R2
3		
4		
5		
6		
7		





















8		
9		
10		
11		
12		
13		
14		
15		
16		
17		





















18		
19		
20		
21		
22		
23		
24		
25		
26		
27		





















28		
29		
30		
31		
32		
33		
34		
35		
36		
37		





















38		
39		
40		
41		
42		
43		
44		
45		
46		
47		





















48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		





















59		
60		
61		
62		
63		
64		
65		
66		
67		
68		

























69		
70		
71		
72		
73		
74		
75		
76		
77		
78		























79		
80		
81		
82		
83		
84		
85		
86		
87		
88		

89		
90		
91		
92		
93		
94		
95		
96		
97		
98		

99		
100		
101		
102		
103		
104		
105		
106		
107		
108		

109		
110		
111		
112		
113		
114		
115		
116		
117		
118		

119		
120		
121		
122		
123		
124		
125		
126		
127		
128		
129		
130		

131		
132		
133		
134		
135		
136		
137		
138		
139		
140		
141		
















142		
143		
144		

Table 2



Example #	R1	R2
146		Me
147		Me
148		Me
149		H
150		Me
151		Me
152		Me

153		Me
-----	---	----

and pharmaceutically acceptable salts, enantiomers, diastereomers or in vivo hydrolysable esters or mixtures thereof.

12. A method according to claim 11 wherein the compound is:
- 5 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 10 acetamide;
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-
 cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers,
 diastereomers or in vivo hydrolysable esters or mixtures thereof.

13. A method according to claim 12 wherein the compound is:
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide; or
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-
 acetamide; or pharmaceutically acceptable salts, enantiomers, diastereomers or in vivo
 hydrolysable esters or mixtures thereof.

14. A method according to claim 10 wherein the compound of
 formula I is combined with one or more known drugs selected from beta-lactams,
 aminoglycosides, inhibitors of beta-lactamase, renal tubular blocking agents and
 inhibitors of metabolising enzymes, N-acylated amino acids.

15. A method according to claim 14 wherein the known drugs are
 selected from the group consisting of imipenem, meropenem, vancomycin, cilastatin,
 cefoxitin, penicillin, clavulanic acid, probenecid, tetracycline, ciprofloxacin, and
 norfloxacin or a mixture thereof, wherein when imipenem is used as a drug it is used
 30 in combination with cilastatin as PRIMAXIN®.